Treatment of the psychotic patient who is violent

Psychiatric Clinics of North America

Volumn 26, Issue 1, 2003, Pages 231-272

  Buckley, Peter F ^a   Noffsinger, Stephen G ^b,c   Smith, Douglas A ^b,c,d   Hrouda, Debra R ^b   Knoll IV, James L ^e  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c ODMH Northcoast Behavioral Healthcare   (United States)

^d MEDICAL COLLEGE OF OHIO   (United States)

^e DARTMOUTH COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CARBAMAZEPINE; CLOZAPINE; FLUNITRAZEPAM; FLUPHENAZINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LORAZEPAM; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PHENYTOIN; QUETIAPINE; RISPERIDONE; TOPIRAMATE; TRAZODONE; VALPROIC ACID; ZIPRASIDONE;

AGGRESSION; ANTICHOLINERGIC EFFECT; BEHAVIOR THERAPY; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG FORMULATION; FORENSIC PSYCHIATRY; HEALTH CARE COST; HIGH RISK POPULATION; HOSTILITY; HUMAN; HUMAN RIGHTS; HYPOTENSION; LEGAL ASPECT; LONG TERM CARE; MENTAL HEALTH CARE; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; SEDATION; SIDE EFFECT; SOCIOLOGY; TARDIVE DYSKINESIA; VIOLENCE;

ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; PSYCHOTHERAPY; PSYCHOTIC DISORDERS; RISK FACTORS; VIOLENCE;

EID: 0037351134     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0193-953X(02)00029-1     Document Type: Review

References (158)

1. Torrey EF. Evaluation of the relationship between violence and serious mental illness. Hosp Community Psychiatry 1994;45:842-8.
2. Arboleda-Florez J, Holley H, Crisanti A. Understanding causal paths between mental illness and violence. Soc Psychiatry Psychiatric Epidemiol 1998;33(Suppl 1):S38-S46.
3. US Department of Justice, Bureau of Justice Statistics. Criminal victimization in the United States, 1992. US Department of Justice Publication NCJ-1 45125. Washington, DC: US Department of Justice; 1994.
4. US Department of Justice, Bureau of Justice Statistics. Criminal victimization 2000: bhanges 1993-2000. US Department of Justice Publication NCJ-187007. Washington, DC: US Department of Justice; 2001.
5. Taylor PJ. Schizophrenia and the risk of violence. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. Oxford: Blackwell Science; 1995. p. 163-183.
6. Wessley S. The epidemiology of crime, violence and schizophrenia. Br J Psychiatry 1997;170:8-11.
7. Link BG, Stueve A. New evidence on the violence risk posed by people with mental illness. Arch Gen Psychiatry 1998;55:403-4.
8. Taylor PJ, Leese M, Williams D, Butwell M, Daly R, Larkin E. Mental disorder and violence. Br J Psychiatry 1998;172:218-26.
9. Angermeyer MC. Schizophrenia and violence. Acta Psychiatr Scand 2000;102(Suppl 407):63-7.
10. Swanson J, Holzer C, Gantu V, Jono R. Violence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment Area Surveys. Hosp Comm Psychiatry 1990;41:761-70.
11. Steadman HJ, Mulvey EP, Monahan J, Rotbins PC, Appelbaum PS, Grisso T, et al. Violence by people discharged from acute psychiatric inpatient facilities and by others in the same neighborhoods. Arch Gen Psychiatry 1998;55:393-401.
12. Swartz MS, Swanson JW, Hiday VA, Borum R, Wagner HR, Burns BJ. Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. Am J Psychiatry 1998;155:226-31.
13. Wallace C, Mullen P, Burgess P, Palmer S, Ruschena D, Browne C. Serious criminal offending and mental disorder. Br J Psychiatry 1998;172:477-84.
14. Tardiff K, Marzuk PM, Leon AC, Portera L. A prospective study of violence by psychiatric patients after hospital discharge. Psychiatr Serv 1997;48:678-81.
15. Lindquist P, Allebeck P. Schizophrenia and assaultive behavior: the role of alcohol and drug abuse. Acta Psychiatr Scand 1989;82:191-5.
16. Volavka J. The neurobiology of violence. Washington, DC: American Psychiatric Press; 2002.
17. Asberg M, Traksman L, Thoren P. 5 HIAA in the cerebrospinal fluid: a biochemical suicide predictor? Arch Gen Psychiatry 1976;33:1193-7.
18. Brown GL, Goodwin FK, Ballenger JC. Aggression in humans correlates with cerebrospinal fluid metabolite. Psychiatry Res 1979;1:131-9.
19. Linnoila M, Virkkunen M, Scheinen M. Low cerebrospinal fluid 5 hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci 1983;33:2609-14.
20. Hibbeln JR, Umhau JC, Linnoila M, George DT, Ragan PW, Shoaf SE, et al. A replication study of violent and nonviolent subjects: cerebrospinal fluid metabolites of serotonin and dopamine are predicted by plasma essential fatty acids. Biol Psychiatry 1998;44:243-9.
21. Moeller FG, Allen T, Cherek DR, Dougherty DM, Lane S, Swann AC. Ipsapirone neuroendocrine challenge: relationship to aggression as measured in the human laboratory. Psychiatr Res 1998;81:31-8.
22. Klassen D, O'Connor WA. A prospective study of predictors of violence in adult male mental health admissions. Law Hum Behav 1988;12:143-58.
23. Shah SA. Dangerousness: a paradigm for exploring some issues in law and psychology. Am Psychol 1978;33:224-38.
24. Junginger J. Predicting compliance with command hallucinations. Am J Psychiatry 1990;147:245-7.
25. Junginger J. Command hallucinations and the prediction of dangerousness. Psychiatr Serv 1995;46:911-4.
26. Link BG, Andrews H, Cullen FT. The violent and illegal behaviour of mental patients reconsidered. Am Sociol Rev 1992;57:275-92.
27. Hafner H, Boker W. Crimes of violence by mentally abnormal offenders: a psychiatric and epidemiological study in the Federal Republic of Germany. Cambridge: Cambridge University Press; 1982.
28. D'Orban P, O'Connor A. Women who kill their parents. Br J Psychiatry 1989;154:27-33.
29. Straznickas KA, McNeil DE, Binder RL. Violence toward family caregivers by mentally ill relatives. Hosp Community Psychiatry 1993;44:385-7.
30. Pinals DA, Noffsinger SG. Characterization of symptoms in NGRI patients. Presented at the 28th annual meeting of the American Academy of Psychiatry and the Law. Denver, 1997.
31. Swanson J, Borum R, Swartz M. Psychotic symptoms and disorders and risk of violent behaviour in the community. Criminal Behav Ment Health 1996;6:317-38.
32. Appelbaum P, Robbins P, Monahan J. Violence and delusions: data from the MacArthur Violence Risk Assessment Study. Am J Psychiatry 2000;157:566-72.
33. Tengstrom A, Hodgins S, Kullgren G. Men with schizophrenia who behave violently: the usefulness of an early- versus late-start offender typology. Schizophr Bull 2001;27:205-18.
34. Swanson J, Swartz M, Estroff S, Borum R, Wagner R, Hiday V. Psychiatric impairment, social contact, and violent behavior: evidence from a study of outpatient-committed persons with severe mental disorder. Soc Psychiatry Psychiatr Epidemiol 1998;33(Suppl 1):S86-S94.
35. Estroff SE, Swanson JW, Lachicotte WS, Swartz M, Bolduc M. Risk reconsidered: targets of violence in the social networks of people with serious psychiatric disorders. Soc Psychiatry Psychiatr Epidemiol 1998;33(Suppl 1):S95-S101.
36. Kho K, Sensky T, Mortimer A, Corcos C. Prospective study into factors associated with aggressive incidents in psychiatric acute admission wards. Br J Psychiatry 1998;172:38-43.
37. Owen C, Tarantello C, Jones M, Tennant C. Violence and aggression in psychiatric units. Psychiatr Serv 1998;49:1452-7.
38. McNiel DE, Binder RL, Greenfield TK. Predictors of violence in civilly committed acute psychiatric patients. Am J Psychiatry 1988;145:965-70.
39. Arango C, Barba A, Gonzalez-Salvador T, Ordonez A. Violence in inpatients with schizophrenia: a prospective study. Schizophr Bull 1999;25:493-503.
40. Tuninger E, Levander S, Bernce R, Johansson G. Criminality and aggression among psychotic in-patients: frequency and clinical correlates. Acta Psychiatr Scand 2001;103:294-300.
41. Harris GT, Rice ME. Risk appraisal and management of violent behavior. Psychiatr Serv 1997;48:1168-76.
42. Resnick PJ, Scott CL. Legal issues in treating perpetrators and victims of violence. Psychiatr Clin N Am 1997;20:473-87.
43. Joint Commission on Healthcare Accreditation. 2002 Hospital accreditation standards. Oakbrook Terrace, IL: Joint Commission Resources; 2002.
44. Centers for Medicare and Medicaid Services. Standards for mental health services. Washington, DC; 2002 Available at www.hcfa.gov/quality/4b2.htm.
45. Corrigan PW, Yudosfsky SC, Silver JM. Pharmacological and behavioral treatments for aggressive psychiatric inpatients. Hosp Community Psychiatry 1993;44:125-33.
46. www.NAMI.org
47. Glazer WM, Dickson RA. Clozapine reduces violence and persistent aggression in schizophrenia. J Clin Psychiatry 1998;59:8-14
48. Taylor PJ, Buckley PF. Treating aggression in the context of psychosis. In: Buckley PF, Waddington JL, editors. Schizophrenia and mood disorders: the new drug therapies in clinical practice. London: Arnold Publications; 2000.
49. Mowerman S, Sins SG. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. Ann Clin Psychiatry 1996;8:193-7.
50. Lehman AF, Steinwachs DM, the PORT Co-Investigators. Translating research into practice: the schizophrenia PORT treatment recommendations. Schizophr Bull 1998;24:1-10.
51. Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP. The Expert Consensus Guideline Series: Treatment of behavioral emergencies. Postgrad Med 2001;May(Spec No):1-88.
52. Buckley PF. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. J Clin Psychiatry 1999;60(Suppl 10):52-60.
53. Swift RH, Hararigan EP, Vankammen DP. A comparison of intramuscular ziprasidone with IM haloperidol. Schizophr Res 1999;36:298.
54. Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158:1149-51.
55. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001;62:153-7.
56. Simpson G, Currier G, et al. Risperidone treatment of agitated psychotic patients. Presented annual meeting of the American College of Neuropsychopharmacology. Hawaii, December 2001.
57. Expert Consensus Guidelines Series. Treatment of schizophrenia 1999. J Clin Psychiatry 1999.
58. Dugan DJ, Vertees JE, Saklad SR, Richards AM, Ershefsky L. Antipsychotic polypharmacy in treatment-resistant schizophrenia. Schizophr Res 1999;36:278.
59. Weiden PJ, Casey DE. Polypharmacy in the treatment of schizophrenia. J Pract Psych Behav Health 1999;5:229-33.
60. Still DJ, Dorson PG, Crimson ML, Pousson C. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 1996;47:1382-4.
61. Weiden P, Aquila R, Dalheim L, Standard JM. Switching antipsychotic medications. J Clin Psychiatry 1997;58(Suppl 10):68-72.
62. Krakowski ML, Kunz M, Czolor P, Volavka J. Long-term high-dose neuroleptic treatment: who gets it and why? Hosp Community Psychiatry 1993;44:640-4.
63. Hirsch SR, Barnes TRE. High-dose neuroleptic therapy. Br J Psychiatry 1994;164:81-6.
64. Dorevitch A, Katz N, Zemishlany Z, Aizenberg D, Weizman A. Intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. Am J Psychiatry 1999;156:142-4.
65. Glazer WM, Kane JM. Depot neuroleptics therapy: an underutilized treatment option. J Clin Psychiatry 1989;53:426-30.
66. Schultz SC, McGorry P. Traditional antipsychotic medications: Contemporary clinical use. In: Buckley PF, Waddington JL, editors. Schizophrenia and mood disorders: the new drug therapies in clinical practice. London: Arnold Publications; 2000. p. 14-20.
67. Munetz M. Can mandatory treatment be therapeutic. New directions in mental health services. Series Number 75. San Francisco: Jossey-Bass; 1997.
68. Kane JM, Keith S, et al. Risperidal Consta: a long-acting intramuscular preparation of risperidone for the treatment of schizophreinia. Presented at annual meeting of the American College of Neuropsychopharmacology. Hawaii, December 2001.
69. Wilson WH. Clinical review of clozapine treatment in state hospital. Hosp Community Psych 1992;43:700-3.
70. Ebrahim GM, Gibler B, Gacono CB, Hayes G. Patient response to clozapine in a forensic psychiatric hospital. Hosp Community Psychiatry 1994;45:271-3.
71. Chiles J, Davidson P, McBride D. Effects of clozapine on use of seclusion and restraint in a state hospital. Hosp Community Psychiatry 1994;45:269-71.
72. Mallya AR, Roos PD, Colgan KR. Restraint, seclusion and clozapine. J Clin Psychiatry 1992;53:395-7.
73. Buckley P, Bartell J, Donenwirth K, Lee S, Torigoe F, Schulz SC. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995;23:607-11.
74. Spivak B, Mester R, Wittenberg N, et al. Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patients. Clin Neuropharmacol 1997;20:442-6.
75. Maier GJ. The impact of clozapine on 25 forensic patients. Bull Am Acad Psychiatry Law 1992;20:247-51.
76. Volavka J, Zito J, Vitral J, Czobor P. Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol 1993;13:287-9.
77. Rabinowitz J, Avon M, Rosenberg V. Effect of clozapine on physical and verbal aggression. Schizophr Res 1996;22:249-55.
78. Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001;50:898-911.
79. Frankle W, Shera D, Berger-Hershkowitz H, Evins A, Connolly C, Goff D, Henderson D. Clozapine-associated reduction in arrest rates of psychotic patients with criminal histories. Am J Psychiatry 2001;158:270-4.
80. Chengappa KNR, Sheth S, Brar JS, Marcus S, Parepally H, Gopalani A, et al. A clinical audit of the first 142 patients who received risperidone at a state psychiatric hospital. J Clin Psychiatry 1999;60:373-8.
81. Kelly L, Nelson MW, Love RC, et al. Risperidone versus olanzapine: discharge rates and economic considerations. Schizophr Res 1999;36:343.
82. Buckley PF, Ibrahim ZY, Singer B, Orr B, Brar PS. Aggression and schizophrenia: efficacy of risperidone. J Am Acad Psychiatry and Law 1997;25:173-81.
83. Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995;15:243-9.
84. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M, for the Risperidone Study Group. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999;60:107-15.
85. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A double-blind placebo controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998;55:633-41.
86. Findling RL. Risperidone for conduct disorder. Annual meeting of the American College of Neuropsychopharmacology. Puerto Rico, December 1999.
87. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results on an international collaborative trial. Am J Psychiatry 1997;154:457-65.
88. Beasley CM, Sayler ME, Kiesler GM, Potvin JH, Sanger TM, Tollefson GD. The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia. Schizophr Res 1998;29:28.
89. Buckley PF, Wiggins LD, Sebastian S, Singer B. Treatment-refractory schizophrenia. Curr Psychiatry Rep 2001;3:393-400.
90. Sanders RD, Mossman D. An open trial of olanzapine in patients with treatment-refractory psychoses. J Clin Psychopharmacol 1999;10:62-6.
91. Street J, Clark WS, Gannos KS, Mitan S, Kadan D, Tamura R, Tollefson GD. Olanzapine in the treatment of psychosis and behavioral disturbances associated with Alzheimer's disease. Schizophr Res 1999;36:298.
92. Portenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders - open-label pilot study. J Clin Psychopharmacol 1999;19:37-44.
93. Small JG, Hirsch SR, Arvantis LA, et al. Quetiapine in patients with schizophrenia. Arch Gen Psychiatry 1997;54:549-52.
94. Hellewell JSE, Cameron-Hands D, Cantillon M. Seroquel: evidence for efficacy in the treatment of hostility and aggression. Schizophr Res 1998;29:154-5.
95. McManus DQ, Arvantis LA, Kowalcyk BB, for the Seroquel Trial 48 group. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry 1999;60:292-8.
96. Buckley PF. Ziprasidone: pharmacology, clinical progress, and therapeutic progress. Drugs of Today 2000;36:583-9.
97. Davis R, Markham A. Ziprasidone. CNS Drugs 1997;8:153-9.
98. Fava M. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin N Am 1997;20:427-51.
99. Luchins DL, Dojka K. Lithium and propranolol in aggression and self-injurious behavior in the mentally retarded. Psychopharmacol Bull 1989;25:372-5.
100. Okuma T, Yamashita I, Takahashi R, et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizphrenia and schizoaffective disorders. Acta Psychiatr Scand 1989;80:250-9.
101. Carpenter WT, Jurz R, Kirkpatrick B, et al. Carbamazepine maintenance treatment in outpatient schizophrenics. Arch Gen Psychiatry 1991;48:69-72.
102. Grossman F. A review of anticonvulsants in treating agitated demented elderly patients. Pharmacotherapy 1998;18:600-6.
103. Casey DE. A controlled trial of valproic acid as an adjunct to treatment of acute schizophrenia. Presented at American Psychiatric Association. Philadelphia, May 2002.
104. Ratey JJ, Sorgi P, O'Driscoll GA, et al. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. J Clin Psychiatry 1992;53:41-6.
105. Gardner W, Lidz C, Hoge S, Monahan J, Eisenberg M, Bennett N, et al. Patient's revisions of their beliefs about the need for hospitalization. Am J Psychiatry 1999;156:1385-91.
106. Frese FJ III, Advocacy, recovery, and the challenges of consumerism for schizophrenia. Psychiatri Clin N Am 1998;21:233-50.
107. Wettstein R. The right to refuse psychiatric treatment. Psychiatri Clin N Am 1999;22:173-82.
108. Appelbaum P, Gutheil T. Clinical handbook of psychiatry and the law. 3rd edition. Baltimore: Williams & Wilkins; 2000.
109. Roth L, Meisel A, Lidz C. Tests of competency to consent to treatment. Am J Psychiatry 1977;134:279-84.
110. Appelbaum P, Grisso T. Assessing patient's capacities to consent to treatment. N Engl J Med 1988;319:1635-8.
111. Grisso T, Appelbaum P. MacArthur Competence Assessment Tool For Treatment (MacCAT-T). Sarasota, FL: Professional Resource Press; 1998.
112. Billick S, Burget W, Friberg G, et al. A clinical study of competency to consent to treatment in pediatrics. J Am Acad Psychiatry Law 2001;29:298-302.
113. Hoge S. Treatment refusal in psychiatric practice. In: Rosner R, editor. Principles and practice of forensic psychiatry. New York: Chapman & Hall; 1994. p. 127-32.
114. Appelbaum P. Almost a revolution. New York: Oxford; 1994.
115. Wyatt v. Stickney (1972), 344 F. Supp. 373 (M.D. Ala.).
116. Washington v. Harrper (1990), 494 US 210.
117. Rennie v. Klein (1983), 720 F 2d 266 (3rd Circ).
118. Rogers v. Commissioner (1983), 458 NE 2d 308 (Mass Sup Jud Ct).
119. A. E. and R. R. v. Mitchell, Number C78-466 (D - Utah, 1980).
120. Appelbaum P. The right to refuse treatment with antipsychotic medications: restrospect and prospect. Am J Psychiatry 1988;145:413-9.
121. Appelbaum P, Hoge S. The right to refuse treatment: what the research reveals. Behav Sci Law 1986;4:279-92.
122. Marder SR. Facilitating compliance with antipsychotic medication. J Clin Psychiatry 1998;59(Suppl 3):21-5.
123. Van Putten T. Why do patients who have schizophrenia refuse to take their drugs? Arch Gen Psychiatry 1974;31:67-72.
124. Barnes TR, McPhillips MA. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry 1999;174:34-43.
125. Amador XE, Gorman JM. Psychopathologic domains and insight in schizophrenia. Psychiatr Clin N Am 1998;21:27-42.
126. Weiner B, Wettstein R. Legal issues in mental health care. New York: Plenum; 1993.
127. Bloch S, Chodoff P, Green S, editors. Psychiatric ethics. 3rd edition. New York: Oxford University Press; 1999.
128. Group for the Advancement of Psychiatry. Forced into treatment: the role of coercion in clinical practice. Washington, DC: American Psychiatric Press; 1994.
129. Milone R. Involuntary hospitalization. In: Ethics, a primer of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 2001.
130. Gardner W, Lidz CW, Hoge SK, Monahan J, Eisenberg MM, Bennett NS, Mulvey EP, Roth LH. Patients' revision of their beliefs about the need for hospitalization. Am J Psychiatry 1999;156:1385-91.
131. Kemp R, Kirov G, Everitt B, David A. Randomized controlled trial of compliance therapy: 18 month follow up. Br J Psychiatry 1998;172:413-9.
132. Winick BJ. Advance directive instruments for those with mental illness. Univ Miami Law Rev 1996;51:57-95.
133. Swanson J, Tepper M, Backlar P, Swartz M. Psychiatric advance directives: an alternative to coercive treatment? Psychiatry 2000;63:160-72.
134. Backlar P, McFarland B. A survey on use of advance directives for mental health treatment in Oregon. Psychiatr Serv 1996;47:1387-9.
135. Geller J. The use of advance directives by persons with serious mental illness for psychiatric treatment. Psychiatr Q 2000;71:1-13.
136. Monahan J, Bonnie R, Appelbaum P, Hyde P, Steadman H, Swartz M. Mandated community treatment: beyond outpatient commitment. Psychiatr Serv 2001;52:1198-205.
137. Srebnik D, La Fond J. Advance directives for mental health treatment. Psychiatr Serv 1999;50:919-25.
138. Miller R. Coerced treatment in the community. Psychiatr Clin N Am 1999;22:183-96.
139. Gerbasi J, Bonnie R, Binder R. Resource document on mandatory outpatient treatment. J Am Acad Psychiatry Law 2000;28:127-44.
140. Fernandez G, Nygard S. Impact of involuntary outpatient commitment on the revolving-door syndrome in North Carolina. Hosp Community Psychiatry 1990;41:1001-4.
141. Van Putten R, Santiago J, Berren M. Involuntary outpatient commitment in Arizona: a restrospective study. Hosp Community Psychiatry 1988;39:953-8.
142. Swartz M, Swanson J, Wagner H, Burns B, Hiday V, Borum R. Can involuntary outpatient commitment reduce hospital recidivism? Findings from a randomized trial with severely mentally ill individuals. Am J Psychiatry 1999;156:1968-75.
143. Swartz M, Swanson J, Hiday V, Wagner H, Burns B, Borum R. Randomized controlled trial of outpatient commitment in North Carolina. Psychiatr Serv 2001;52:325-9.
144. Steadman H, Gounis K, Dennis D, Hopper K, Roche B, Swartz M, et al. Assessing the New York City involuntary outpatient commitment pilot program. Psychiatr Serv 2001;52:330-41.
145. O'Reilly R. Does involuntary out-patient treatment work? Psychiatr Bull 2001;25:371-4.
146. Zonana H. Mandated outpatient treatment: a quick fix for random violence? Not likely. J Am Acad Psychiatry Law 2000;28:124-6.
147. NY CLS Men Hyg §9.60 (Kendra's Law, Assisted outpatient treatment "AOT") (1999).
148. Gutheil T. Paranoia and progress notes: A guide to forensically informed psychiatric record keeping. Hosp Community Psychiatry 1980;31:479-82.
149. Lipari v. Sears, 497 F. Supp. 185 (D. Neb. 1980).
150. Tarasoft v. Regents of the University of California, 551 P 2d 334 (Cal 1976).
151. McNeil DE, Binder RL, Fulton FM. Management of threats of violence under California's duty-to-protect statute. Am J Psychiatry 1998;155:1097-101.
152. Brennan T, Sox C, Burstin H. Relation between negligent adverse events and the outcomes of medical-malpractice litigation. N Engl J Med 1996;335:1963-7.
153. Madison C. When psychiatric patients go on shooting sprees... Rx for Risk 1999;7.
154. Steadman HJ, Williams Deane M, Borum R, Morrissey JP. Comparing outcomes of major models of police responses to mental health emergencies. Psychiatr Serv 2000;51:645-9.
155. Steadman HJ, Stainbrook KA, Griffin P, Draine J, Dupont R, Horey C. A specialized crisis response site as a core element of police-based diversion programs. Psychiatr Serv 2001;52:219-22.
156. Torrey EF. Mental illness: confronting America's crisis. New York: Harper Publications; 1997.
157. Lamb HR, Weinberger LE. Persons with severe mental illness in jails and prisons: a review. Psychiatr Serv 1998;49:483-92.
158. Treatment of inmates and probationers. NCJ 174463. Washington, DC: US Department of Justice; 1999.